SlideShare ist ein Scribd-Unternehmen logo
1 von 24
Downloaden Sie, um offline zu lesen
Expression and Purification of Virulence Factors
A Novel Approach for Identifying Drug Targets for
Autoimmune and Inflammatory Diseases
David Bienvenue, Ph.D.
VLST Corporation
Viral Logic Systems Technology
VLST
• Privately-held company founded in 2004
• ~35 Employees
• Focused on exploiting viral evolution to develop novel
biotherapeutics
• Based in “sunny” Seattle, WA
Office view:
July 8th, 2009, 3:43 PM
Office view:
The other 364 days of 2009
Virulence Factors as a
Novel Route to Therapeutics
Identify
virulence
factors
Identify
cellular
targets
Define biologic
consequences
of interaction
Develop therapeutics
mimicking
virulence factors
Drug Development Strategy
• Some viral proteins modulate/suppress host immune system
• Facilitate viral infection and influence severity of disease
• Can be homologous or unrelated to host genes
• Targets of viral proteins validated as treatment methods for
autoimmune/inflammatory illness
Discovery of Viral TNF Receptor
Key Step in Development of Enbrel®
Smith et al (1990) Science 248: 1019
Smith et al (1991) BBRC 176: 335
Shope fibroma
virus-T2
TNFR2
(p75)
TNFR1
(p55)
Fc
Enbrel®
(Entanercept)
Cys-rich
domains
Dimerization
domain
29 % sequence
identity
38 % sequence
identity
Cytokines, Chemokines and Their
Receptors Encoded by Herpes Viruses
Alcami (2003)
Nat Rev
Immunol 3: 36
Genomic Scale Search
for Viral Virulence Factors
~18,500 viral proteins
in VLST database
~6,500 viral protein clusters of similar
proteins
>600 putative virulence factors
identified and queued for screening
Bioinformatic Expert System
selection criteria
Topology – anchor, secreted, other
transmembrane
Homology to human proteins
Species
Sequence cluster membership
N-Linked glycosylation sites
Virulence
Pfam motifs
Non-essential for viral replication
Analyzed 267 viral genomes
98 pox viruses
96 herpes viruses
62 adeno viruses
11 asfar viruses
Identification of Host Targets of
Virulence Factors
Target
identification
by LC-LTQ MS
Bind target(s) from conditioned
media, cell lysates from
immune-related cell lines,
using tandem affinity tag
Transiently express
tagged viral proteins
Bioinformatic mining for
virulence factors
Synthesize
viral genes
VF
VF
VF
FACS screen and
Bioassay panel
Transient Expression of Viral Proteins
Challenge:
• Need high-throughput method to generate conditioned
media for target discovery (goal ~20-30/wk)
• Adherent transfections not easily scaleable
• Scale up via technology, not FTE’s!
Solution:
• Transition away from adherent 293-EBNA’s, to
suspension transient transfections
Invitrogen’s FreeStyle™ MAX
Transfection System
• Optimized system for suspension CHO and HEK293 cells
– Media and transfection reagent chemically defined,
serum free
– Cells adapted for suspension culture in FreeStyle™
media
• One shake flask vs. many T-flasks
– Less labor intensive, higher throughput
Effect of Cell line, Vector in Freestyle
•Same gene in different vectors and cell lines
•Similar expression levels, GS vector has slight advantage
Comparison of Day 4 Titers
40.9
56.3
36.8
43.1 43.6
30.7
40.6 40.0
45.2
26.7
51.9 50.5
0
10
20
30
40
50
60293F-CHEF
293F-GS
293F-409
CHOF-CHEF
CHOF-GS
CHOF-409
CHO-EBCHEF
CHO-EBGS
CHO-EB-409
293-EB-CHEF
293-EB-GS
293-EB-409
ug/mL
Viral Protein Expression
Target Discovery is a Numbers Game
Proteins expressed
Proteins screened
Targets identified
• Majority of putative virulence factors express in 293’s
• Some 293 non-expressors can be expressed in CHO
• Maximize number of viral factors going into screen
• Minimize effort, reagents spent on non-expressors
24-well Shake Plate Prescreen
• Reagent, time and effort wasted on large-scale transients, if
protein doesn’t express
• Typically if vectors failed in 293, re-try in CHO
Goal
• Minimize effort re-transfecting viral proteins in CHO
• Attempt prescreen expression in in 24-well shaker plates
– Mimic conditions in 100 mL shake flasks
– Try ~70 constructs that didn’t previously express in 293’s
CHO-EBNA transients, Anti HA blot
CHO Expression, 24-well Plate
High-throughput Prescreen
•~30% (21 of 70) expressed in
CHO
•Pre-screen all viral ORFs in
293 and CHO
•Only perform larger transients
on vectors positive for
expression
• “HAC”- tandem affinity tag expressed on one end of
virulence factor
• Multi-epitope tag, used for purification and target discovery
• Possibility that HAC may block binding to target
• May also impact protein expression/secretion
N- And C-Tagged Virulence Factors
HAC
Tag
Affinity Resin
Expression of N- and C-tagged
Viral Proteins
• Gene synthesize both N- and C-term. tagged versions
• >90% express at least one version
– ~20% increase over expressing C-tag alone
• Increases probability of identifying targets
– In some cases, only one version binds target
Viral Protein Expression
Salvage Strategy
Express in 293’s
24-well pre-screen?
100 mL scale-up
and screen
Yes
No Express in CHO 24-well
prescreen?
Yes No
STOP
START
100 mL scale-up
and screen
•Use DNA from CRO to perform prescreen
•Minimize resources for DNA prep and large scale transients
“No viral protein left behind”
• Plan on evaluating some viral factors in vivo, mouse
inflammation models
• Need quantity of protein that can’t easily be obtained via
transient transfection
• Codon-optimize gene expression in mammalian cells
• Add restriction sites to subclone into CHEF (CMC- ICOS) or
GS (Lonza) expression vectors
• Utilize Genetix “Clonepix” colony picker to facilitate clone
picking process
Generation of Stable CHO Cell Lines
Large-scale Viral Protein Production
Clonepix-Based Colony Picking
•Secreted product detected via fluor.
labeled probe
•Evaluate fluorescence compared to
colony size
•Useful method for weeding out low/non-
expressing clones
•Permits screening thousands, vs.
hundreds of colonies
•Results in increased titer of final
production clone (relative to limiting
dilution cloning and picking)
Purification Development
High-throughput Screening
Atoll GmbH
Atoll Media scout kit
•100 µL / 200 µL formats
•8 diff. resins per class
ProA
Anion
Cation
CHA
HIC
Millipore Vacuum Manifold
•Screen multiple conditions
quickly and easily
•Facilitates use of “Design of
Experiments”
•Consumes little protein
HTS-Capacity Determination
•Plate format quickly identified high capacity CEX
resin
Multi-Angle Light Scattering To
Characterize Viral Proteins
UV LS RI
Wyatt TREOS
Wyatt Optilab
DSP RefractometerTosoh 3000SWxl
•Determine multimer state of novel viral proteins
•Often have several glycosylation sites
•Shape-dependent effects increase error of MW derived
from std. curve of other proteins
Solution: Use SEC with Multi-Angle Light Scattering
Agilent
HPLC
5480-FLAG MALS
UV trace
Total mass (Peptide + CHO)
226 kDa
Peptide: 160 kDa
CHO: 66 kDa
5480-HAC monomer
Theor. peptide MW: 24 kDa
160/24= ~6.7
(Multi-Angle Light Scattering)
VLST Platform Highlights
•Identified numerous immunologically relevant targets
•Validated targets of 4 approved, 11 investigational
drugs
•Partnership with Novo Nordisk in 2008 to provide
research targets
•Therapeutic programs based on viral targets entering the
clinic in 2010/2011
Acknowledgements
Bioinformatics and Proteomics
• Stefan Ponko, Ph.D.
• Ajamete Kaykas, Ph.D.
Protein Sciences Group
• Jeff Bartron
• Chris Tompkins
• Laura Hajny
• Patrick Mosher
• Ryan Kelly
• Ryan Merrill

Weitere ähnliche Inhalte

Was ist angesagt?

Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...MilliporeSigma
 
Holistic Approaches to Virus Risk Mitigation
Holistic Approaches to Virus Risk MitigationHolistic Approaches to Virus Risk Mitigation
Holistic Approaches to Virus Risk MitigationMilliporeSigma
 
Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...
Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...
Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...Merck Life Sciences
 
Development of diagnostic kits
Development of diagnostic kitsDevelopment of diagnostic kits
Development of diagnostic kitsshiney chatak
 
Current methods for plant disease diagnosis
Current methods for plant disease diagnosisCurrent methods for plant disease diagnosis
Current methods for plant disease diagnosisSHIVANI PATHAK
 
Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell Proteins
Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell ProteinsBreaking the Status Quo: Using Mass Spectrometry to detect Host Cell Proteins
Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell ProteinsMerck Life Sciences
 
Effective detection of MLN pathogens in leaf tissues and seed lots
Effective detection of MLN pathogens in leaf tissues and seed lotsEffective detection of MLN pathogens in leaf tissues and seed lots
Effective detection of MLN pathogens in leaf tissues and seed lotsCIMMYT
 
Xpert- MTB-RIF Data _Biman
Xpert- MTB-RIF Data _BimanXpert- MTB-RIF Data _Biman
Xpert- MTB-RIF Data _BimanBiman Dey
 
quarantine by sahadeo kuwardadra
quarantine by sahadeo kuwardadraquarantine by sahadeo kuwardadra
quarantine by sahadeo kuwardadrasahadeo kuwardadra
 
Microbiology Meets Mass Spectrometry
Microbiology Meets Mass SpectrometryMicrobiology Meets Mass Spectrometry
Microbiology Meets Mass SpectrometryMargie Morgan
 
Mycobacterium molecular diagnosis
Mycobacterium molecular diagnosisMycobacterium molecular diagnosis
Mycobacterium molecular diagnosisBayan Nusairat
 
Oncolytic Virotherapy Basic Knowledge Review - Ceative Biolabs
Oncolytic Virotherapy Basic Knowledge Review - Ceative BiolabsOncolytic Virotherapy Basic Knowledge Review - Ceative Biolabs
Oncolytic Virotherapy Basic Knowledge Review - Ceative BiolabsCreative-Biolabs
 
Moleecular mechanism of disease diagnosis
Moleecular mechanism of disease diagnosisMoleecular mechanism of disease diagnosis
Moleecular mechanism of disease diagnosisjeeva raj
 
Diagnostic process
Diagnostic processDiagnostic process
Diagnostic processILRI
 
Anti Virus Biomolecular Discovery - Creative Biolabs
Anti Virus Biomolecular Discovery - Creative BiolabsAnti Virus Biomolecular Discovery - Creative Biolabs
Anti Virus Biomolecular Discovery - Creative BiolabsCreative-Biolabs
 
Intro to biotech final presentation
Intro to biotech final presentationIntro to biotech final presentation
Intro to biotech final presentationAnjali Chandani
 
detect and identify common human bacterial pathogens in high purity water.
detect and identify common human bacterial pathogens in high purity water.detect and identify common human bacterial pathogens in high purity water.
detect and identify common human bacterial pathogens in high purity water.Saad Farooqi
 
Newer diagnostic methods for tuberculosis
Newer  diagnostic  methods for tuberculosis  Newer  diagnostic  methods for tuberculosis
Newer diagnostic methods for tuberculosis Shweta Anand
 

Was ist angesagt? (20)

Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...
 
Holistic Approaches to Virus Risk Mitigation
Holistic Approaches to Virus Risk MitigationHolistic Approaches to Virus Risk Mitigation
Holistic Approaches to Virus Risk Mitigation
 
Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...
Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...
Unveiling the Potential of your AAV Gene Therapy: Orthogonal methods to under...
 
Development of diagnostic kits
Development of diagnostic kitsDevelopment of diagnostic kits
Development of diagnostic kits
 
Current methods for plant disease diagnosis
Current methods for plant disease diagnosisCurrent methods for plant disease diagnosis
Current methods for plant disease diagnosis
 
Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell Proteins
Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell ProteinsBreaking the Status Quo: Using Mass Spectrometry to detect Host Cell Proteins
Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell Proteins
 
Effective detection of MLN pathogens in leaf tissues and seed lots
Effective detection of MLN pathogens in leaf tissues and seed lotsEffective detection of MLN pathogens in leaf tissues and seed lots
Effective detection of MLN pathogens in leaf tissues and seed lots
 
Xpert- MTB-RIF Data _Biman
Xpert- MTB-RIF Data _BimanXpert- MTB-RIF Data _Biman
Xpert- MTB-RIF Data _Biman
 
quarantine by sahadeo kuwardadra
quarantine by sahadeo kuwardadraquarantine by sahadeo kuwardadra
quarantine by sahadeo kuwardadra
 
Microbiology Meets Mass Spectrometry
Microbiology Meets Mass SpectrometryMicrobiology Meets Mass Spectrometry
Microbiology Meets Mass Spectrometry
 
Mycobacterium molecular diagnosis
Mycobacterium molecular diagnosisMycobacterium molecular diagnosis
Mycobacterium molecular diagnosis
 
Oncolytic Virotherapy Basic Knowledge Review - Ceative Biolabs
Oncolytic Virotherapy Basic Knowledge Review - Ceative BiolabsOncolytic Virotherapy Basic Knowledge Review - Ceative Biolabs
Oncolytic Virotherapy Basic Knowledge Review - Ceative Biolabs
 
ESTABLISHING MYCOBACTERIOLOGY LABORATORY SERVICES
ESTABLISHING MYCOBACTERIOLOGY LABORATORY SERVICESESTABLISHING MYCOBACTERIOLOGY LABORATORY SERVICES
ESTABLISHING MYCOBACTERIOLOGY LABORATORY SERVICES
 
Moleecular mechanism of disease diagnosis
Moleecular mechanism of disease diagnosisMoleecular mechanism of disease diagnosis
Moleecular mechanism of disease diagnosis
 
First Coast Final
First Coast FinalFirst Coast Final
First Coast Final
 
Diagnostic process
Diagnostic processDiagnostic process
Diagnostic process
 
Anti Virus Biomolecular Discovery - Creative Biolabs
Anti Virus Biomolecular Discovery - Creative BiolabsAnti Virus Biomolecular Discovery - Creative Biolabs
Anti Virus Biomolecular Discovery - Creative Biolabs
 
Intro to biotech final presentation
Intro to biotech final presentationIntro to biotech final presentation
Intro to biotech final presentation
 
detect and identify common human bacterial pathogens in high purity water.
detect and identify common human bacterial pathogens in high purity water.detect and identify common human bacterial pathogens in high purity water.
detect and identify common human bacterial pathogens in high purity water.
 
Newer diagnostic methods for tuberculosis
Newer  diagnostic  methods for tuberculosis  Newer  diagnostic  methods for tuberculosis
Newer diagnostic methods for tuberculosis
 

Ähnlich wie 2010 Pep Talk Presentation

Does your cell line have a secret avoid surprises with characterization
Does your cell line have a secret avoid surprises with characterizationDoes your cell line have a secret avoid surprises with characterization
Does your cell line have a secret avoid surprises with characterizationMilliporeSigma
 
Canopy BioSciences August 2017
Canopy BioSciences August 2017Canopy BioSciences August 2017
Canopy BioSciences August 2017Jens-Ole Bock
 
Demonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsDemonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsMerck Life Sciences
 
Demonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsDemonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsMilliporeSigma
 
CAR-T Cell Products Validation
CAR-T Cell Products ValidationCAR-T Cell Products Validation
CAR-T Cell Products ValidationCreative-Biolabs
 
Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Promises and Challenges of Manufacturing and Testing Viral Producer Cell LinesPromises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Promises and Challenges of Manufacturing and Testing Viral Producer Cell LinesMerck Life Sciences
 
Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Promises and Challenges of Manufacturing and Testing Viral Producer Cell LinesPromises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Promises and Challenges of Manufacturing and Testing Viral Producer Cell LinesMilliporeSigma
 
Microbiome Identification to Characterization: Pathogen Detection Webinar Ser...
Microbiome Identification to Characterization: Pathogen Detection Webinar Ser...Microbiome Identification to Characterization: Pathogen Detection Webinar Ser...
Microbiome Identification to Characterization: Pathogen Detection Webinar Ser...QIAGEN
 
Cytokine Detection Technology.pdf
Cytokine Detection Technology.pdfCytokine Detection Technology.pdf
Cytokine Detection Technology.pdfCreative Proteomics
 
Next Generation Recombinant Protein Manufacturing
Next Generation Recombinant Protein ManufacturingNext Generation Recombinant Protein Manufacturing
Next Generation Recombinant Protein ManufacturingKBI Biopharma
 
Krista's Presentation at the 2019 SFAF Meeting
Krista's Presentation at the 2019 SFAF Meeting Krista's Presentation at the 2019 SFAF Meeting
Krista's Presentation at the 2019 SFAF Meeting Krista Ternus
 
Setting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund AngSetting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund AngMilliporeSigma
 
Setting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund AngSetting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund AngMerck Life Sciences
 
Assignment on Preclinical and clinical screening of anti cancer drugs
Assignment on Preclinical and clinical screening of anti cancer drugsAssignment on Preclinical and clinical screening of anti cancer drugs
Assignment on Preclinical and clinical screening of anti cancer drugsDeepak Kumar
 
High throughput screening
High throughput screening High throughput screening
High throughput screening RewariBhavya
 
Tissue culture and virology (cpe, plaque assay)
Tissue culture and virology (cpe, plaque assay)Tissue culture and virology (cpe, plaque assay)
Tissue culture and virology (cpe, plaque assay)Noman-Hafeez khosa
 
High throughput screenig
High throughput screenigHigh throughput screenig
High throughput screenigShakeel Sha
 

Ähnlich wie 2010 Pep Talk Presentation (20)

Does your cell line have a secret avoid surprises with characterization
Does your cell line have a secret avoid surprises with characterizationDoes your cell line have a secret avoid surprises with characterization
Does your cell line have a secret avoid surprises with characterization
 
Canopy BioSciences August 2017
Canopy BioSciences August 2017Canopy BioSciences August 2017
Canopy BioSciences August 2017
 
Demonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsDemonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey Platforms
 
Demonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey PlatformsDemonstrating Process Scalability with Robust and Turnkey Platforms
Demonstrating Process Scalability with Robust and Turnkey Platforms
 
CAR-T Cell Products Validation
CAR-T Cell Products ValidationCAR-T Cell Products Validation
CAR-T Cell Products Validation
 
Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Promises and Challenges of Manufacturing and Testing Viral Producer Cell LinesPromises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
 
Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Promises and Challenges of Manufacturing and Testing Viral Producer Cell LinesPromises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
 
Microbiome Identification to Characterization: Pathogen Detection Webinar Ser...
Microbiome Identification to Characterization: Pathogen Detection Webinar Ser...Microbiome Identification to Characterization: Pathogen Detection Webinar Ser...
Microbiome Identification to Characterization: Pathogen Detection Webinar Ser...
 
Cytokine Detection Technologies
Cytokine Detection TechnologiesCytokine Detection Technologies
Cytokine Detection Technologies
 
Cytokine Detection Technology.pdf
Cytokine Detection Technology.pdfCytokine Detection Technology.pdf
Cytokine Detection Technology.pdf
 
Next Generation Recombinant Protein Manufacturing
Next Generation Recombinant Protein ManufacturingNext Generation Recombinant Protein Manufacturing
Next Generation Recombinant Protein Manufacturing
 
Axt microarrays
Axt microarraysAxt microarrays
Axt microarrays
 
Krista's Presentation at the 2019 SFAF Meeting
Krista's Presentation at the 2019 SFAF Meeting Krista's Presentation at the 2019 SFAF Meeting
Krista's Presentation at the 2019 SFAF Meeting
 
Setting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund AngSetting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund Ang
 
Setting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund AngSetting up for successful lot release testing by Edmund Ang
Setting up for successful lot release testing by Edmund Ang
 
Assignment on Preclinical and clinical screening of anti cancer drugs
Assignment on Preclinical and clinical screening of anti cancer drugsAssignment on Preclinical and clinical screening of anti cancer drugs
Assignment on Preclinical and clinical screening of anti cancer drugs
 
Lisa_Grimm
Lisa_GrimmLisa_Grimm
Lisa_Grimm
 
High throughput screening
High throughput screening High throughput screening
High throughput screening
 
Tissue culture and virology (cpe, plaque assay)
Tissue culture and virology (cpe, plaque assay)Tissue culture and virology (cpe, plaque assay)
Tissue culture and virology (cpe, plaque assay)
 
High throughput screenig
High throughput screenigHigh throughput screenig
High throughput screenig
 

Kürzlich hochgeladen

Take control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test SuiteTake control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test SuiteDianaGray10
 
Are Multi-Cloud and Serverless Good or Bad?
Are Multi-Cloud and Serverless Good or Bad?Are Multi-Cloud and Serverless Good or Bad?
Are Multi-Cloud and Serverless Good or Bad?Mattias Andersson
 
SALESFORCE EDUCATION CLOUD | FEXLE SERVICES
SALESFORCE EDUCATION CLOUD | FEXLE SERVICESSALESFORCE EDUCATION CLOUD | FEXLE SERVICES
SALESFORCE EDUCATION CLOUD | FEXLE SERVICESmohitsingh558521
 
Ensuring Technical Readiness For Copilot in Microsoft 365
Ensuring Technical Readiness For Copilot in Microsoft 365Ensuring Technical Readiness For Copilot in Microsoft 365
Ensuring Technical Readiness For Copilot in Microsoft 3652toLead Limited
 
"Debugging python applications inside k8s environment", Andrii Soldatenko
"Debugging python applications inside k8s environment", Andrii Soldatenko"Debugging python applications inside k8s environment", Andrii Soldatenko
"Debugging python applications inside k8s environment", Andrii SoldatenkoFwdays
 
Dev Dives: Streamline document processing with UiPath Studio Web
Dev Dives: Streamline document processing with UiPath Studio WebDev Dives: Streamline document processing with UiPath Studio Web
Dev Dives: Streamline document processing with UiPath Studio WebUiPathCommunity
 
Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024BookNet Canada
 
"ML in Production",Oleksandr Bagan
"ML in Production",Oleksandr Bagan"ML in Production",Oleksandr Bagan
"ML in Production",Oleksandr BaganFwdays
 
unit 4 immunoblotting technique complete.pptx
unit 4 immunoblotting technique complete.pptxunit 4 immunoblotting technique complete.pptx
unit 4 immunoblotting technique complete.pptxBkGupta21
 
A Deep Dive on Passkeys: FIDO Paris Seminar.pptx
A Deep Dive on Passkeys: FIDO Paris Seminar.pptxA Deep Dive on Passkeys: FIDO Paris Seminar.pptx
A Deep Dive on Passkeys: FIDO Paris Seminar.pptxLoriGlavin3
 
Commit 2024 - Secret Management made easy
Commit 2024 - Secret Management made easyCommit 2024 - Secret Management made easy
Commit 2024 - Secret Management made easyAlfredo García Lavilla
 
SAP Build Work Zone - Overview L2-L3.pptx
SAP Build Work Zone - Overview L2-L3.pptxSAP Build Work Zone - Overview L2-L3.pptx
SAP Build Work Zone - Overview L2-L3.pptxNavinnSomaal
 
Unleash Your Potential - Namagunga Girls Coding Club
Unleash Your Potential - Namagunga Girls Coding ClubUnleash Your Potential - Namagunga Girls Coding Club
Unleash Your Potential - Namagunga Girls Coding ClubKalema Edgar
 
DSPy a system for AI to Write Prompts and Do Fine Tuning
DSPy a system for AI to Write Prompts and Do Fine TuningDSPy a system for AI to Write Prompts and Do Fine Tuning
DSPy a system for AI to Write Prompts and Do Fine TuningLars Bell
 
Digital Identity is Under Attack: FIDO Paris Seminar.pptx
Digital Identity is Under Attack: FIDO Paris Seminar.pptxDigital Identity is Under Attack: FIDO Paris Seminar.pptx
Digital Identity is Under Attack: FIDO Paris Seminar.pptxLoriGlavin3
 
TrustArc Webinar - How to Build Consumer Trust Through Data Privacy
TrustArc Webinar - How to Build Consumer Trust Through Data PrivacyTrustArc Webinar - How to Build Consumer Trust Through Data Privacy
TrustArc Webinar - How to Build Consumer Trust Through Data PrivacyTrustArc
 
Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)
Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)
Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)Mark Simos
 
Hyperautomation and AI/ML: A Strategy for Digital Transformation Success.pdf
Hyperautomation and AI/ML: A Strategy for Digital Transformation Success.pdfHyperautomation and AI/ML: A Strategy for Digital Transformation Success.pdf
Hyperautomation and AI/ML: A Strategy for Digital Transformation Success.pdfPrecisely
 
New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024BookNet Canada
 
TeamStation AI System Report LATAM IT Salaries 2024
TeamStation AI System Report LATAM IT Salaries 2024TeamStation AI System Report LATAM IT Salaries 2024
TeamStation AI System Report LATAM IT Salaries 2024Lonnie McRorey
 

Kürzlich hochgeladen (20)

Take control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test SuiteTake control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test Suite
 
Are Multi-Cloud and Serverless Good or Bad?
Are Multi-Cloud and Serverless Good or Bad?Are Multi-Cloud and Serverless Good or Bad?
Are Multi-Cloud and Serverless Good or Bad?
 
SALESFORCE EDUCATION CLOUD | FEXLE SERVICES
SALESFORCE EDUCATION CLOUD | FEXLE SERVICESSALESFORCE EDUCATION CLOUD | FEXLE SERVICES
SALESFORCE EDUCATION CLOUD | FEXLE SERVICES
 
Ensuring Technical Readiness For Copilot in Microsoft 365
Ensuring Technical Readiness For Copilot in Microsoft 365Ensuring Technical Readiness For Copilot in Microsoft 365
Ensuring Technical Readiness For Copilot in Microsoft 365
 
"Debugging python applications inside k8s environment", Andrii Soldatenko
"Debugging python applications inside k8s environment", Andrii Soldatenko"Debugging python applications inside k8s environment", Andrii Soldatenko
"Debugging python applications inside k8s environment", Andrii Soldatenko
 
Dev Dives: Streamline document processing with UiPath Studio Web
Dev Dives: Streamline document processing with UiPath Studio WebDev Dives: Streamline document processing with UiPath Studio Web
Dev Dives: Streamline document processing with UiPath Studio Web
 
Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
 
"ML in Production",Oleksandr Bagan
"ML in Production",Oleksandr Bagan"ML in Production",Oleksandr Bagan
"ML in Production",Oleksandr Bagan
 
unit 4 immunoblotting technique complete.pptx
unit 4 immunoblotting technique complete.pptxunit 4 immunoblotting technique complete.pptx
unit 4 immunoblotting technique complete.pptx
 
A Deep Dive on Passkeys: FIDO Paris Seminar.pptx
A Deep Dive on Passkeys: FIDO Paris Seminar.pptxA Deep Dive on Passkeys: FIDO Paris Seminar.pptx
A Deep Dive on Passkeys: FIDO Paris Seminar.pptx
 
Commit 2024 - Secret Management made easy
Commit 2024 - Secret Management made easyCommit 2024 - Secret Management made easy
Commit 2024 - Secret Management made easy
 
SAP Build Work Zone - Overview L2-L3.pptx
SAP Build Work Zone - Overview L2-L3.pptxSAP Build Work Zone - Overview L2-L3.pptx
SAP Build Work Zone - Overview L2-L3.pptx
 
Unleash Your Potential - Namagunga Girls Coding Club
Unleash Your Potential - Namagunga Girls Coding ClubUnleash Your Potential - Namagunga Girls Coding Club
Unleash Your Potential - Namagunga Girls Coding Club
 
DSPy a system for AI to Write Prompts and Do Fine Tuning
DSPy a system for AI to Write Prompts and Do Fine TuningDSPy a system for AI to Write Prompts and Do Fine Tuning
DSPy a system for AI to Write Prompts and Do Fine Tuning
 
Digital Identity is Under Attack: FIDO Paris Seminar.pptx
Digital Identity is Under Attack: FIDO Paris Seminar.pptxDigital Identity is Under Attack: FIDO Paris Seminar.pptx
Digital Identity is Under Attack: FIDO Paris Seminar.pptx
 
TrustArc Webinar - How to Build Consumer Trust Through Data Privacy
TrustArc Webinar - How to Build Consumer Trust Through Data PrivacyTrustArc Webinar - How to Build Consumer Trust Through Data Privacy
TrustArc Webinar - How to Build Consumer Trust Through Data Privacy
 
Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)
Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)
Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)
 
Hyperautomation and AI/ML: A Strategy for Digital Transformation Success.pdf
Hyperautomation and AI/ML: A Strategy for Digital Transformation Success.pdfHyperautomation and AI/ML: A Strategy for Digital Transformation Success.pdf
Hyperautomation and AI/ML: A Strategy for Digital Transformation Success.pdf
 
New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
 
TeamStation AI System Report LATAM IT Salaries 2024
TeamStation AI System Report LATAM IT Salaries 2024TeamStation AI System Report LATAM IT Salaries 2024
TeamStation AI System Report LATAM IT Salaries 2024
 

2010 Pep Talk Presentation

  • 1. Expression and Purification of Virulence Factors A Novel Approach for Identifying Drug Targets for Autoimmune and Inflammatory Diseases David Bienvenue, Ph.D. VLST Corporation
  • 2. Viral Logic Systems Technology VLST • Privately-held company founded in 2004 • ~35 Employees • Focused on exploiting viral evolution to develop novel biotherapeutics • Based in “sunny” Seattle, WA Office view: July 8th, 2009, 3:43 PM Office view: The other 364 days of 2009
  • 3. Virulence Factors as a Novel Route to Therapeutics Identify virulence factors Identify cellular targets Define biologic consequences of interaction Develop therapeutics mimicking virulence factors Drug Development Strategy • Some viral proteins modulate/suppress host immune system • Facilitate viral infection and influence severity of disease • Can be homologous or unrelated to host genes • Targets of viral proteins validated as treatment methods for autoimmune/inflammatory illness
  • 4. Discovery of Viral TNF Receptor Key Step in Development of Enbrel® Smith et al (1990) Science 248: 1019 Smith et al (1991) BBRC 176: 335 Shope fibroma virus-T2 TNFR2 (p75) TNFR1 (p55) Fc Enbrel® (Entanercept) Cys-rich domains Dimerization domain 29 % sequence identity 38 % sequence identity
  • 5. Cytokines, Chemokines and Their Receptors Encoded by Herpes Viruses Alcami (2003) Nat Rev Immunol 3: 36
  • 6. Genomic Scale Search for Viral Virulence Factors ~18,500 viral proteins in VLST database ~6,500 viral protein clusters of similar proteins >600 putative virulence factors identified and queued for screening Bioinformatic Expert System selection criteria Topology – anchor, secreted, other transmembrane Homology to human proteins Species Sequence cluster membership N-Linked glycosylation sites Virulence Pfam motifs Non-essential for viral replication Analyzed 267 viral genomes 98 pox viruses 96 herpes viruses 62 adeno viruses 11 asfar viruses
  • 7. Identification of Host Targets of Virulence Factors Target identification by LC-LTQ MS Bind target(s) from conditioned media, cell lysates from immune-related cell lines, using tandem affinity tag Transiently express tagged viral proteins Bioinformatic mining for virulence factors Synthesize viral genes VF VF VF FACS screen and Bioassay panel
  • 8. Transient Expression of Viral Proteins Challenge: • Need high-throughput method to generate conditioned media for target discovery (goal ~20-30/wk) • Adherent transfections not easily scaleable • Scale up via technology, not FTE’s! Solution: • Transition away from adherent 293-EBNA’s, to suspension transient transfections
  • 9. Invitrogen’s FreeStyle™ MAX Transfection System • Optimized system for suspension CHO and HEK293 cells – Media and transfection reagent chemically defined, serum free – Cells adapted for suspension culture in FreeStyle™ media • One shake flask vs. many T-flasks – Less labor intensive, higher throughput
  • 10. Effect of Cell line, Vector in Freestyle •Same gene in different vectors and cell lines •Similar expression levels, GS vector has slight advantage Comparison of Day 4 Titers 40.9 56.3 36.8 43.1 43.6 30.7 40.6 40.0 45.2 26.7 51.9 50.5 0 10 20 30 40 50 60293F-CHEF 293F-GS 293F-409 CHOF-CHEF CHOF-GS CHOF-409 CHO-EBCHEF CHO-EBGS CHO-EB-409 293-EB-CHEF 293-EB-GS 293-EB-409 ug/mL
  • 11. Viral Protein Expression Target Discovery is a Numbers Game Proteins expressed Proteins screened Targets identified • Majority of putative virulence factors express in 293’s • Some 293 non-expressors can be expressed in CHO • Maximize number of viral factors going into screen • Minimize effort, reagents spent on non-expressors
  • 12. 24-well Shake Plate Prescreen • Reagent, time and effort wasted on large-scale transients, if protein doesn’t express • Typically if vectors failed in 293, re-try in CHO Goal • Minimize effort re-transfecting viral proteins in CHO • Attempt prescreen expression in in 24-well shaker plates – Mimic conditions in 100 mL shake flasks – Try ~70 constructs that didn’t previously express in 293’s
  • 13. CHO-EBNA transients, Anti HA blot CHO Expression, 24-well Plate High-throughput Prescreen •~30% (21 of 70) expressed in CHO •Pre-screen all viral ORFs in 293 and CHO •Only perform larger transients on vectors positive for expression
  • 14. • “HAC”- tandem affinity tag expressed on one end of virulence factor • Multi-epitope tag, used for purification and target discovery • Possibility that HAC may block binding to target • May also impact protein expression/secretion N- And C-Tagged Virulence Factors HAC Tag Affinity Resin
  • 15. Expression of N- and C-tagged Viral Proteins • Gene synthesize both N- and C-term. tagged versions • >90% express at least one version – ~20% increase over expressing C-tag alone • Increases probability of identifying targets – In some cases, only one version binds target
  • 16. Viral Protein Expression Salvage Strategy Express in 293’s 24-well pre-screen? 100 mL scale-up and screen Yes No Express in CHO 24-well prescreen? Yes No STOP START 100 mL scale-up and screen •Use DNA from CRO to perform prescreen •Minimize resources for DNA prep and large scale transients “No viral protein left behind”
  • 17. • Plan on evaluating some viral factors in vivo, mouse inflammation models • Need quantity of protein that can’t easily be obtained via transient transfection • Codon-optimize gene expression in mammalian cells • Add restriction sites to subclone into CHEF (CMC- ICOS) or GS (Lonza) expression vectors • Utilize Genetix “Clonepix” colony picker to facilitate clone picking process Generation of Stable CHO Cell Lines Large-scale Viral Protein Production
  • 18. Clonepix-Based Colony Picking •Secreted product detected via fluor. labeled probe •Evaluate fluorescence compared to colony size •Useful method for weeding out low/non- expressing clones •Permits screening thousands, vs. hundreds of colonies •Results in increased titer of final production clone (relative to limiting dilution cloning and picking)
  • 19. Purification Development High-throughput Screening Atoll GmbH Atoll Media scout kit •100 µL / 200 µL formats •8 diff. resins per class ProA Anion Cation CHA HIC Millipore Vacuum Manifold •Screen multiple conditions quickly and easily •Facilitates use of “Design of Experiments” •Consumes little protein
  • 20. HTS-Capacity Determination •Plate format quickly identified high capacity CEX resin
  • 21. Multi-Angle Light Scattering To Characterize Viral Proteins UV LS RI Wyatt TREOS Wyatt Optilab DSP RefractometerTosoh 3000SWxl •Determine multimer state of novel viral proteins •Often have several glycosylation sites •Shape-dependent effects increase error of MW derived from std. curve of other proteins Solution: Use SEC with Multi-Angle Light Scattering Agilent HPLC
  • 22. 5480-FLAG MALS UV trace Total mass (Peptide + CHO) 226 kDa Peptide: 160 kDa CHO: 66 kDa 5480-HAC monomer Theor. peptide MW: 24 kDa 160/24= ~6.7 (Multi-Angle Light Scattering)
  • 23. VLST Platform Highlights •Identified numerous immunologically relevant targets •Validated targets of 4 approved, 11 investigational drugs •Partnership with Novo Nordisk in 2008 to provide research targets •Therapeutic programs based on viral targets entering the clinic in 2010/2011
  • 24. Acknowledgements Bioinformatics and Proteomics • Stefan Ponko, Ph.D. • Ajamete Kaykas, Ph.D. Protein Sciences Group • Jeff Bartron • Chris Tompkins • Laura Hajny • Patrick Mosher • Ryan Kelly • Ryan Merrill